StartseiteAlle MolekülePSMA
PSMA
PSMA
PSMA Molekülinformation
Molecule Name
Prostate-Specific Membrane Antigen
Molekülalias
FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP
Drug Development Progress
Anzahl der klinischen Arzneimittel161
Anzahl der inverkehr gebrachten Arzneimittel6
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
EC:3.4.17.21，GIG27，Glutamate carboxypeptidase II，NAALADase I，FOLH，Cell growth-inhibiting gene 27 protein，PSM，N-acetylated-alpha-linked acidic dipeptidase I，GCPII，Folylpoly-gamma-glutamate carboxypeptidase，Folate hydrolase 1，FOLH1，Pteroylpoly-Gamma-Glutamate Carboxypeptidase，Membrane Glutamate Carboxypeptidase，Glutamate Carboxypeptidase 2，Glutamate Carboxylase II，NAALAD1，FGCP，PSMA，MGCP，Folate Hydrolase (Prostate-Specific Membrane Antigen) 1，N-Acetylated Alpha-Linked Acidic Dipeptidase 1，Prostate Specific Membrane Antigen Variant F，Prostate-Specific Membrane Antigen，EC 3.4.17.21，NAALAdase，GCP2
PSMA Produktliste
No Data
You Have Viewed 0 Of 0 Results
- 1
No Data
No Data
Can’t find what you need?
Submit your requirements and our technical
team will help.
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| 225 Actinium PSMA-617 | 225Ac-PSMA-617; 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817 | Phase 3 Clinical | Advanced Accelerator Applications Sa, Endocyte Inc, Novartis Pharma Ag | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Gallium-68 PSMA-617 | 68Ga-DKFZ-617; Gallium-68-PSMA-617; 68Ga-PSMA-33; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; 68Ga-PSMA-617; PSMA-617-[68Ga]; 225 Ac-PSMA-617 | Phase 3 Clinical | Peking Union Medical College Hospital | Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
| Ga-68 PSMA-093 | Ga-68 P16-093; PSMA-93 Latest; PSMA-093; HBED-CC-PHENOXY-PSMA; [68Ga]P16-093 | Phase 3 Clinical | Five Eleven Pharma Inc, Indiana University, Peking Union Medical College Hospital | Glioma; Kidney Neoplasms; Prostatic Neoplasms; Sjogren's Syndrome | Details |
| Vidoflufolastat (18F) | CTT-1057-F-18; CTT-1057-18F; 18F-CTT1057; CTT-1057 | Phase 3 Clinical | Cancer Targeted Technology Llc, Washington University | Carcinoma, Renal Cell; Prostatic Neoplasms | Details |
| Lu-177-labeled PSMA ligands (Zentralklinik Bad Berka/Johns Hopkins University School of Medicine) | Phase 3 Clinical | Zentralklinik Bad Berka | Kidney Neoplasms; Prostatic Neoplasms | Details | |
| Lutetium-177 zadavotide guraxetan | Phase 3 Clinical | Curium Us Llc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| INR-101 | INR101; INR-101; INR101 PET CT; INR101-PET/CT | Phase 3 Clinical | Cloud Nuclear Medicine (Tianjin) Co Ltd | Diagnostic agents; Prostatic Neoplasms | Details |
| 68Ga-NYM032 | 68Ga-NYM032; 68Ga-NY108; 68GaNYM032 | Phase 3 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| Nizaracianine triflutate | ZW800-1 | Phase 3 Clinical | Curadel Surgical Innovations Inc, Leiden University Medical Center | Ureteral Diseases | Details |
| ITM-24D | ITM-24D; 68Ga-PSMA-TTM | Phase 3 Clinical | ITM Isotope Technologies Munich SE | Prostatic Neoplasms | Details |
| 18F vipivotide tetraxetan | Al18F-PSMA-617; 18F-PSMA-617 | Phase 3 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms | Details |
| HRS-4357 | HRS-4357; HRS4357 | Phase 3 Clinical | Tianjin Hengrui Pharmaceutical Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 64Cu-PSMA I&T | Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T; Copper Cu 64 PSMA I&T | Phase 3 Clinical | Curium Us Llc | Prostatic Neoplasms | Details |
| 64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 3 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| 177Lu-DOTA-rosopatamb | 177Lu-DOTA-TLX591-CHO; TLX591 | Phase 3 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [Lu177]-PNT-2002 | PNT-2002; [Lu-177]-PNT-2002; 177Lu-PNT2002; [Lu-177]-PSMA-I&T; 177Lu-PSMA-I&T | Phase 3 Clinical | Scintomics | Carcinoma, Adenoid Cystic; Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| F-18 Florastamin | FC-303 | Phase 3 Clinical | Futurechem | Prostatic Neoplasms | Details |
| Lutetium-177-PSMA-I&T | Phase 2 Clinical | Radboud University Nijmegen | Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Salivary Gland Neoplasms | Details | |
| 68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms | Details | |
| [18F]DCFBC | [18F]DCFBC | Phase 2 Clinical | Sidney Kimmel Cancer Center, Washington University | Prostatic Neoplasms | Details |
| 177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
| Nezastomig | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 225Ac-J591 | 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α; J591-Ac-225 | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
| ATL-101 | J-591; Lu-177-J591; 177Lu-J591; muJ-591; huJ-591; MLN-591; MLN-591RL; ATL-101 | Phase 2 Clinical | Weill Medical College of Cornell University | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Glioma; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms | Details |
| [131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466; 131I-MIP-1095; 131-I-MIP-1466; 131I-MIP-1466 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 225Ac-rhPSMA-10.1 | Phase 2 Clinical | Blue Earth Therapeutics Ltd | Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| CONV-01-alpha + PSMA I&T | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms | Details | |
| Terbium 161- PSMA I&T | Phase 2 Clinical | Oncosia Scientific GmbH | Prostatic Neoplasms | Details | |
| [18F]PSMA-11 | F-18 PSMA-11; 18F-PSMA-11; [18F]-AlF-PSMA-11; [18F]AlF-PSMA-11 | Phase 2 Clinical | Ghent University Hospital | Prostatic Neoplasms; Thyroid Neoplasms | Details |
| PB-011 | PB011; PB-011 | Phase 2 Clinical | Primo Biotechnology Co Ltd | Neoplasms; Prostatic Neoplasms | Details |
| 68Ga-PSMA-CYC | 68Ga-PSMA-CYC | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details |
| TD-001 | TD-001 | Phase 2 Clinical | T.O.A.D. Oncology SA | Prostatic Neoplasms, Castration-Resistant | Details |
| MHB-048C | MHB048C; MHB-048C | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| GSK-5458514 | GSK-5458514; GSK5458514 | Phase 2 Clinical | Glaxosmithkline Plc | Prostatic Neoplasms | Details |
| 161Tb-NYM032 | 161Tb-NYM032 | Phase 2 Clinical | Institute Of Nuclear Physics And Chemistry Chinese Academy Of Engineering Physics, Mianyang Central Hospital, Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| INR-102 | [177Lu]Lu-PSMA-137; INR102; INR-102 | Phase 2 Clinical | Cloud Nuclear Medicine (Tianjin) Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| RHN001-Dx (99mTc-PSMA) | technetium-99m (99mTc); Technetium 99m-RHN 001; 99mTc-RHN001 | Phase 2 Clinical | Heidelberg University Hospital, Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| RHN001-Tx (188Re-PSMA) | rhenium-188- RHN 001; RHN001-Tx (188Re-PSMA); Rhenium-188 RHN 001 (188Re) | Phase 2 Clinical | Heidelberg University Hospital, Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| AS-1986NS | AS-1986NS; AS1986NS | Phase 2 Clinical | Antelope Surgical Solutions Inc | Prostatic Neoplasms | Details |
| GenSci-143 | GenSci-143; GenSci143 | Phase 2 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Alzheimer Disease; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| 225Ac-LNC1011 | 225Ac-LNC-1011; 225Ac-LNC1011 | Phase 2 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| In-111 rosopatamab tetraxetan | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| Ac-225 rosopatamab tetraxetan | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| 68Ga-PSMA-0057 | Phase 2 Clinical | Suzhou Ruihe Pharmaceutical Technology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| 177Lu-LNC1011 | 177LuLNC1011; 177Lu-LNC1011 | Phase 2 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| DGPR-1008 | DGPR1008; DGPR-1008 | Phase 2 Clinical | Xindou Biotechnology (Suzhou) Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| 177Lu-NYM032 | 177Lu-NYM032; 177LuNYM032; 177Lu-NY108 | Phase 2 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-PSMA-0057 | 177Lu-PSMA-0057 | Phase 2 Clinical | Nanjing First Hospital, Nanjing Medical University | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [225Ac]Ac-PSMA-R2 | [225Ac]Ac-PSMA-R2; AAA802; AAA-802 | Phase 2 Clinical | Novartis Pharma Ag | Prostatic Neoplasms | Details |
| 177Lu-PSMA | 177Lu-PSMA | Phase 2 Clinical | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori | Carcinoma, Renal Cell; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms | Details |
| [177Lu]JH020002 | [177Lu]JH020002; JH-002; JH002; 177-Lu JH-020002; Lu 177 JH020002; JH02; JH-02 | Phase 2 Clinical | Bivision Biomedical Technology (Nanjing) Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 131I-PSMA-1095 | 131I-PSMA-1095 | Phase 2 Clinical | Jewish General Hospital | Prostatic Neoplasms | Details |
| 68Ga-HTK03149 | 68Ga-HTK03149 | Phase 2 Clinical | British Columbia Cancer Agency | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-HTK03170 | 177Lu-HTK03170 | Phase 2 Clinical | British Columbia Cancer Agency | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| ADVC-001 | 212Pb-ADVC001; 212 Pb ADVC 001; 212-lead ADVC 001; 212Pd ADVC001; [212Pb]Pb-ADVC-001; ADVC-001 | Phase 2 Clinical | Advancell Advanced In Vitro Cell Technologies Sa | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Ga-68-NGUL | Phase 2 Clinical | Cellbion Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, B-Cell; Lymphoma, B-Cell | Details | |
| GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/PSMA | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| 177Lu-rhPSMA-10.1 | 177Lu-rhPSMA-10.1; 177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu-rhPSMA; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu rhPSMA-10.1 | Phase 2 Clinical | Technical University Munich | Prostatic Diseases; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urogenital Neoplasms | Details |
| Lu-177-DGUL | Lu-177-DGUL; 177Lu-DOTA-GUL; PSMA-D GUL | Phase 2 Clinical | Cellbion Co Ltd | Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 225Actinium-PSMA-I&T | FPI-2265 | Phase 2 Clinical | Excel Diagnostics And Nuclear Oncology Center | Prostatic Neoplasms, Castration-Resistant | Details |
| Olsutamig | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]Ludotadipep | 177Lu-FC705; 177Lu-FC-705 | Phase 2 Clinical | Futurechem | Prostatic Neoplasms, Castration-Resistant | Details |
| 67Cu-SAR-bisPSMA | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| 99m-TC-PSMA-I&S | Phase 2 Clinical | Irccs San Raffaele | Prostatic Neoplasms | Details | |
| IS-002 | IS-002 | Phase 2 Clinical | Intuitive Surgical Medical Device Science & Technology (Shanghai) Co Ltd | Prostatic Neoplasms | Details |
| Zopocianine | OTL-78; OTL78 | Phase 2 Clinical | Endocyte Inc, Purdue University | Prostatic Neoplasms | Details |
| INO-5401 | INO-5401 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Carcinoma, Transitional Cell; Glioblastoma | Details |
| JNJ-63898081 | JNJ-63898081; JNJ-8081 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Neoplasms | Details |
| P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
| PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | BRL Medicine Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| CC-1 | CC-1 | Phase 1 Clinical | BiconY Therapeutics Gmbh | Prostatic Neoplasms | Details |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-EB-vipivotide tetraxetan | [177Lu]Lu-XT033; 177-Lu-EB-PSMA-617 | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd, Peking Union Medical College Hospital | Carcinoma, Adenoid Cystic; Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]-CTT-1403 | CTT-1403; [177Lu]CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403 | Phase 1 Clinical | Cancer Targeted Technology Llc | Prostatic Neoplasms | Details |
| Pelgifatamab corixetan | BAY-2315497 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| anti-PSMA CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details | |
| PSMA CAR-T | Phase 1 Clinical | University Of Pennsylvania | Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms | Details | |
| PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells | Phase 1 Clinical | Shenzhen Misheng Biotechnology Co Ltd | Prostatic Neoplasms; Solid tumours | Details | |
| INO-5412 | INO-5412; INO5412 | Phase 1 Clinical | Inovio Pharmaceuticals Inc | Glioblastoma | Details |
| 161Tb-LNC1011 | 161Tb-LNC1011 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms | Details |
| 225Ac-TR2205 | 225Ac-TR2205 | Phase 1 Clinical | Cancer Hospital of Shandong First Medical University | Triple Negative Breast Neoplasms | Details |
| Chimeric Antigen Receptor T Cells therapy (Orig Stone Biotech) | ACT#001 | Phase 1 Clinical | Orig Stone Biotech(Zhejiang) Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| BAY2616505 | BAY-2616505 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-TWS02 | Phase 1 Clinical | Shandong University, The Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University | Prostatic Neoplasms | Details | |
| 225Ac-TWS02 | Phase 1 Clinical | Shandong University, The Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University | Prostatic Neoplasms | Details | |
| 18F-(FAl)-PSMA | Phase 1 Clinical | Pla General Hospital | Prostatic Neoplasms | Details | |
| 177Lu-PSMA-3Q | Phase 1 Clinical | The First Medical Center Of Chinese People'S Liberation Army General Hospital | Prostatic Neoplasms | Details | |
| 18F-P137 | 18F-P137 | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Nasopharyngeal Carcinoma; Neoplasms | Details |
| 177Lu-ITG-PSMA-1 | 177Lu-ITG-PSMA-1; 177Lu-PSMA-I&T; Lu-177-ITG-PSMA-1 | Phase 1 Clinical | Lausanne University Hospital | Prostatic Neoplasms, Castration-Resistant; Sarcoma | Details |
| [64Cu]Cu-PSMA-R2 | Phase 1 Clinical | Institut De Cancerologie De L Ouest | Prostatic Neoplasms | Details | |
| Anti-PSMA CAR-NK cell therapy (Cancer Hospital Of Chinese Academy Of Medical Sciences) | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Prostatic Neoplasms, Castration-Resistant | Details | |
| [111In]In-FL-020 | Phase 1 Clinical | Full Life Technologies Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| PSMA-VG-01 | PSMA-VG-01 | Phase 1 Clinical | VitsGen Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]Lu-PSMA-XT | [177Lu]Lu-PSMA-XT | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| 64Cu-TR2205 | 64Cu-TR2205; 64CuTR2205 | Phase 1 Clinical | C-Ray Therapeutics (Chengdu) Co Ltd | Diagnostic agents; Prostatic Neoplasms | Details |
| ART-101 (Archeus Technologies) | ART-101 | Phase 1 Clinical | University of Wisconsin–Madison | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| ITM-23 | ITM-23; 161Tb- ITM23 | Phase 1 Clinical | Itm Solucin Gmbh | Prostatic Neoplasms | Details |
| [18F]F-DCFPyL | [18F]F-DCFPyL | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| [18F]AlF-PSMA-N5 | [18F]AlF-PSMA-N5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| [177Lu]Lu-BQ7876 | [177Lu]Lu-BQ7876; Lutetium-177 Labeled BQ7876 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Prostatic Neoplasms | Details |
| 68Ga-AAZTA-NI-093 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details | |
| 61Cu-based NuriPro radiodiagnostic (NUCLIDIUM) | Phase 1 Clinical | Nuclidium AG | Prostatic Neoplasms | Details | |
| IR800-IAB2MA | IR800-IAB2MA | Phase 1 Clinical | Imaginab Inc | Kidney Neoplasms; Prostatic Neoplasms | Details |
| 177Lu-TR0471 | 177Lu-TR0471; 177LuTR0471 | Phase 1 Clinical | C-Ray Therapeutics (Chengdu) Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| [18F]F-PSMA-N5 | [18F]F-PSMA-N5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| PSW-1025 | PSW-1025 | Phase 1 Clinical | Japan Agency For Medical Research And Development, Osaka University | Prostatic Neoplasms | Details |
| 68Ga-AAZTA-093 | 68Ga-AAZTA-093 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details |
| 225Ac-ITM-22 | ITM-22 | Phase 1 Clinical | ITM Radiopharmazie Munchen GmbH | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 99mTc-QULIC-5-P1 | 99mTc-QULIC-5-P1 | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Prostatic Neoplasms | Details |
| 68Ga-PSFA | 68Ga-PSFA | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Adenomatous Polyposis Coli | Details |
| 161Tb-SibuDAB | Phase 1 Clinical | University Hospital Basel | Prostatic Neoplasms, Castration-Resistant | Details | |
| Actinium-225 FL 020 (Full-Life Technologies) | 225-Ac FL-020; 225Ac-FL-020 | Phase 1 Clinical | Full Life Technologies Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| [Ac-225]-PSMA-62 | [Ac-225]-PSMA-62; 225Ac-PSMA-62 | Phase 1 Clinical | Point Biopharma Inc | Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 111In-PSMA-Trillium | BAY3632687; BAY-3632687 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant; Prostatism | Details |
| JNJ-9401 | JNJ-9401 | Phase 1 Clinical | Xencor Inc | Prostatic Neoplasms | Details |
| 68Ga-NTA-476 | 68Ga-NTA-476 | Phase 1 Clinical | 3B Pharmaceuticals GmbH, Genesiscares | Prostatic Neoplasms | Details |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| BAY-3563254 | BAY-3563254; BAY3563254 | Phase 1 Clinical | Noria Therapeutics Inc, PSMA Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatism | Details |
| JNJ-87189401 | JNJ-87189401 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| 99mTc-SY101 | [99mTc]SY101; 99mTc-SY101; 99mTcSY101 | Phase 1 Clinical | Shanghai Shiya Pharmaceutical Technology Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| Actinium-225-macropa-pelgifatamab | BAY-3546828; BAY3546828 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| AMX-500 | VIR-5500; SAR-446329; SAR446329; AMX-500 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| [68Ga]Ga-PSMA-D5 | [68Ga]Ga-PSMA-D5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| 177Lu-LNC1003 | 177Lu-LNC1003 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| HRS-9815 | HRS-9815; HRS9815 | Phase 1 Clinical | Tianjin Hengrui Pharmaceutical Co Ltd | Diagnostic agents; Prostatic Neoplasms | Details |
| PSMA-Targeted [In-111]-Labeled Trillium Compound | Phase 1 Clinical | Ratio Therapeutics Inc | Prostatic Neoplasms | Details | |
| Autologous T cells therapy(Unicar-Therapy) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Prostatic Neoplasms | Details | |
| 212Pb-NG001 | 212Pb-NG001; AB-001; AB001 | Phase 1 Clinical | ARTBIO Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CART-PSMA cells（Nova Therapeutics） | Phase 1 Clinical | Nova Therapeutics LLC | Prostatic Neoplasms | Details | |
| 177Lu-P17-088 | 177Lu-P17-088 | Phase 1 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-P17-087 | 177Lu-P17-087 | Phase 1 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms, Castration-Resistant | Details |
| JANX-007 | PSMA-TRACTr; JANX-007 | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| JNJ-80038114 | JNJ-80038114 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
| DXC-014 | DAC-014; DXC-014 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Melanoma; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| DXC-008 | DAC-008; DXC-008 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Prostatic Neoplasms; Sarcoma, Ewing; Solid tumours | Details |
| TNB-585 | TNB-585; AMG-340 | Phase 1 Clinical | Teneobio Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CB-307 | CB-307; CB307 | Phase 1 Clinical | Crescendo Bioscience Inc | Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Copper 64-DOTA-TLX 592 | 64Cu-TLX-592; 64Cu-DOTA-TLX592 | Phase 1 Clinical | Telix International Pty Ltd | Prostatic Neoplasms | Details |
| ARX-517 | JNJ-95298177; ARX-517; ARX517 | Phase 1 Clinical | Ambrx Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| AVC-102 | AVC-102 | Phase 1 Clinical | AvenCell Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms | Details |
| CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Carcinoma, Renal Cell; Lung Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | Abbvie Inc, The Scripps Research Institute Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics Inc | Neoplasms | Details | |
| CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) | TmPSMA-02 | Phase 1 Clinical | Tmunity Therapeutics Inc, University Of Minnesota, University Of Pennsylvania | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [99mTc]TcO-ABX-474 | Clinical | Helmholtz-Zentrum Dresden-Rossendorf | Prostatic Neoplasms | Details | |
| radiolabeled AZ-093 (Five Eleven Pharma/University of Pennsylvania) | [68Ga]- AZ-093; AZ-093; AZ-093-[177Lu]; AZ-093-68Ga; Lutetium-177-AZ-093; [177Lu]-AZ-093; AZ-093-[68Ga]; AZ-093-177Lu; Gallium-68-AZ-093 | Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details |
| 177Lu-PSMA-1 | Clinical | Centre Léon Bérard | Carcinoma, Renal Cell; Peritoneal Neoplasms; Prostatic Neoplasms | Details | |
| (99m)Tc-MIP-1427 | (99m)Tc-MIP-1427; 99mTc-MIP-1427 | Clinical | Molecular Insight Pharmaceuticals Inc | Prostatic Neoplasms | Details |
| 99mTc-P137 | 99mTc-P137 | Clinical | The First Affiliated Hospital Of Beijing University | Neoplasms | Details |
| 18F-TWS02 | 18F-TWS02 | Clinical | Shandong University | Prostatic Neoplasms | Details |
| [68Ga]Ga-TWS02 | 68Ga-TWS02 | Clinical | Shandong University | Prostatic Neoplasms | Details |
| 68Ga-PSMA | Clinical | The First Affiliated Hospital Of Anhui Medical University | Prostatic Neoplasms | Details | |
| [68Ga]-P137 | Clinical | Beijing Cancer Hospital | Prostatic Neoplasms | Details | |
| 177Lu-PSMA-3D1015 | Clinical | 3d Medicines Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| [At-211] PSMA-5 | [At-211] PSMA-5 | Clinical | Osaka University | Prostatic Neoplasms | Details |
| ⁶⁸Ga-labeled PSMA-targeting tracer (FindCure Biosciences ) | FindCure Biosciences (ZhongShan) Co Ltd | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Capromab pendetide | lndium-CYT-356; CYT-356; Indium-111-CYT-356; 111In CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | Cytogen Corp | 1996-10-28 | Prostatic Neoplasms | Details |
| PB-01 (Primo Biotechnology) | PSMA-1007-[18F]; PB-01 (Primo Biotechnology); PB01 [18F]PSMA-1007; 18F PSMA-1007; [18F]PSMA1007; 18FPSMA-1007; [18F]PSMA-1007; 18F-PSMA-1007; [18F]PSMA 1007 | Approved | Primo Biotechnology Co Ltd | Radelumin | Carcinoma, Renal Cell; Colonic Neoplasms; Prostatic Neoplasms | Details | ||||
| Piflufolastat F 18 | Approved | Johns Hopkins University | Pylarify, Pylclari | United States | Prostatic Neoplasms | Progenics Pharmaceuticals Inc | 2021-05-26 | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Castration-Sensitive Prostate Neoplasms; Diagnostic agents; Genital Neoplasms, Female; Metastatic breast cancer; Neoplasm Metastasis; Pancreatic Neoplasms; Prostatic Neoplasms | Details | |
| TLX-591 companion diagnostic (Telix Pharmaceuticals) | Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11; AAA517; AAA-517; [68Ga]Ga-PSMA-11; TLX591-Sx; 68Ga-PSMA-IRDye; TLX591-CDx; TLX007-CDx | Approved | Advanced Nuclear Medicine Ingredients (Anmi) | Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz | United States | Prostatic Neoplasms | Telix Pharmaceuticals Ltd, University Of California, Los Angeles | 2020-12-01 | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Diagnostic agents; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms | Details |
| Lutetium (177Lu) vipivotide tetraxetan | PSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT | Approved | Radiomedix Inc | PLUVICTO, 派威妥 | United States | Prostatic Neoplasms, Castration-Resistant | Novartis Pharmaceuticals Corp | 2022-03-23 | Anemia; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Cytopenia; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia | Details |
| Flotufolastat F-18 | F-18-rhPSMA-7.3; Fluorine-18 rhPSMA; rhPSMA-7.3 (18F); 18FrhPSMA-7.3; (18F)-rhPSMA-7.3; 18F-rhPSMA-7.3 | Approved | Blue Earth Diagnostics Inc, Technical University Munich | POSLUMA | United States | Prostatic Neoplasms | Blue Earth Diagnostics Ltd | 2023-05-25 | Contrast agents; Prostatic Neoplasms | Details |
M***n2025-09-15I have several Scientists that use Acro Proteins. We used to order these on Fisher, however, I have now changed to directly through Acro as their ordering is so much easier and they fulfill order promptly and perfectly. We are starting to use more Acro products and I am excited to continue to work with this company and keep getting the same great quality of products, ease of ordering, and super quick fulfillment.- T***n2023-06-29I ordered this product on Monday and received it by Friday! The product came neatly packed in dry ice with secure packaging. The reagent gave me good standard curves as I titrate the concentration of PSMA for my assay. I will order again next time.
- T***n2021-09-22I highly recommend for this supplier company .I received this order on Sep . 03 /2021 with enough dry ice for - 80C. Thank you acrobiosystems.